Biosimilars Forum Welcomes Teva as Newest Member
Teva rejoins the growing biosimilar industry group in its work to promote access to lower-cost biosimilars in the U.S.
The Biosimilars Forum has announced Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), as its newest member. Teva rejoins the Biosimilars Forum during a watershed moment for the U.S. biosimilars industry – as the Forum leads the industry’s effort to make lower-cost biosimilars accessible to all patients who need them.
“Teva aspires to be a global leader in biologic medicines, and we are excited to rejoin the Biosimilars Forum and continue our work to deliver high quality, safe and effective biosimilar medicines to U.S. patients,” said Pat McIntosh, Head of U.S. Commercial Generics and Biosimilars at Teva. “Our decision to rejoin the Forum reaffirms our shared value of helping achieve more widespread uptake of biosimilars in the U.S.”
2023 has been a watershed year for biosimilars. Biosimilars have the potential to save $133 billion in U.S. health care spending by 2025, if — and only if — they have full and complete access to formularies. Free-market competition can lower prescription drug costs if biosimilars have better access to formularies.
The Biosimilars Forum works to advance biosimilars adoption and education in the United States with the goals of expanding access and availability of these FDA-approved, lower-cost therapies.
“The Forum’s Board of Directors and I are thrilled to announce Teva as the newest member of the Biosimilars Forum,” said Juliana M. Reed, Executive Director of the Biosimilars Forum. “Teva’s partnership will be invaluable as the Forum spearheads advocacy efforts to ensure biosimilars are available to patients as lower-cost, safe and effective treatment options.”
For more information on the Biosimilars Forum’s work to increase access to lower-cost biosimilars, visit biosimilarsforum.org.